Translational analyses of ATR inhibitor M1774 in a Phase I study in patients with solid tumors (DDRiver Solid Tumors 301)

被引：3
|
作者：
Tolcher, Anthony W.
Yap, Timothy A.
Plummer, Ruth
Grombacher, Thomas
Wang, Danyi
Schaffroth, Corinna
Hicking, Christine
Szucs, Zoltan
Locatelli, Giuseppe
de Bono, Johann S.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT271
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT271
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
    Yoshitaka Seki
    Noboru Yamamoto
    Yosuke Tamura
    Yasushi Goto
    Takashi Shibata
    Maki Tanioka
    Hajime Asahina
    Hiroshi Nokihara
    Yasuhide Yamada
    Takashi Shimamoto
    Kazuo Noguchi
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1099 - 1105
  • [32] Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
    Seki, Yoshitaka
    Yamamoto, Noboru
    Tamura, Yosuke
    Goto, Yasushi
    Shibata, Takashi
    Tanioka, Maki
    Asahina, Hajime
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Shimamoto, Takashi
    Noguchi, Kazuo
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1099 - 1105
  • [33] PHASE I STUDY OF CEDIRANIB, A VEGFR SIGNALING INHIBITOR, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Takahashi, T.
    Yamamoto, N.
    Boku, N.
    Yamazaki, K.
    Yamamoto, N.
    Yamada, Y.
    Yamada, K.
    Shin, E.
    Puchalski, T. A.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2008, 19 : 159 - 159
  • [34] Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors
    Shitara, Kohei
    Yamazaki, Kentaro
    Tsushima, Takahiro
    Naito, Tateaki
    Matsubara, Nobuaki
    Watanabe, Morihiro
    Sarholz, Barbara
    Johne, Andreas
    Doi, Toshihiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (08) : 859 - 866
  • [35] PHASE I STUDY OF PERIFOSINE (AKT INHIBITOR) FOR RECURRENT PEDIATRIC SOLID TUMORS
    Becher, O. J.
    Trippett, T.
    Gilheeney, S.
    Khakoo, Y.
    Lyden, D.
    Haque, S.
    Petriccione, M.
    Camelia, S.
    Lassman, A.
    Fischer, C.
    Kolesar, J.
    Jiang, Z.
    Modak, S.
    Holland, E.
    Dunkel, I.
    NEURO-ONCOLOGY, 2010, 12 (06) : II42 - II42
  • [36] A phase I study of highly potent oral ATR inhibitor (ATRi) tuvusertib plus oral PARP inhibitor (PARPi) niraparib in patients with solid tumors.
    Yap, Timothy A.
    Plummer, Elizabeth Ruth
    Tolcher, Anthony W.
    Szucs, Zoltan
    Gounaris, Ioannis
    Locatelli, Giuseppe
    Enderlin, Marta
    Hicking, Christine
    Mukker, Jatinder Kaur
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Pharmacodynamic (PD) and immunophenotyping analyses of ATR inhibitor (ATRi) tuvusertib plus ATM inhibitor (ATMi) lartesertib in a phase Ib study in patients with advanced unresectable solid tumors
    Boni, Valentina
    Yap, Timothy A.
    Garcia, Enrique Sanz
    Tolcher, Anthony W.
    Sessa, Giuseppe
    Locatelli, Giuseppe
    Manginelli, Angela
    Gerhold-Ay, Aslihan
    Gunhan, Burak Kursad
    Pennock, Gregory K.
    Mukker, Jatinder Kaur
    Gounaris, Ioannis
    Cabanas, Elena Garralda
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] A Phase I Study of GGTI-2418 (Geranylgeranyl Transferase I Inhibitor) in Patients with Advanced Solid Tumors
    Karasic, Thomas B.
    Chiorean, E. Gabriela
    Sebti, Said M.
    O'Dwyer, Peter J.
    TARGETED ONCOLOGY, 2019, 14 (05) : 613 - 618
  • [39] A Phase I Study of GGTI-2418 (Geranylgeranyl Transferase I Inhibitor) in Patients with Advanced Solid Tumors
    Thomas B. Karasic
    E. Gabriela Chiorean
    Said M. Sebti
    Peter J. O’Dwyer
    Targeted Oncology, 2019, 14 : 613 - 618
  • [40] A phase I study of oral ixabepilone in patients with advanced solid tumors
    Deeken, John F.
    Marshall, John L.
    Pishvaian, Michael J.
    Hwang, Jimmy
    Ahlers, Christoph M.
    Clemens, Pamela L.
    Parker, Susan M.
    Iacono, Lisa
    LoRusso, Patricia M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (05) : 1071 - 1078
12345